GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

RICHMOND, VA - Indivior PLC (LON:INDV), a pharmaceutical company specializing in treatments for substance use disorders, ...

Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

(Alliance News) - GSK PLC on Tuesday said applications for its treatment for a type of asthma and chronic rhinosinusitis with nasal polyps, or CRSwNP, have been accepted for review in China, Japan and ...

World’s First “Universal” Robotics Software Platform BOW Raises £4 Million Seed to Reduce Cost and Complexity of Programming ...

The global antacids market is on track for substantial expansion, with projections indicating a rise from USD 6,971.2 million ...

The new collaboration between GSK and the Univeristy of Oxford aims to explore cancer prevention through vaccination.

This European review of the prefilled syringe follows GSK's receipt of approval from the US Food & Drug Administration on January 8. GSK is also investigating submission of the new presentation to ...